Not Yet Recruiting
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
NCT07511036
- Conditions
- Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
- Locations
-
- M.D. Anderson Cancer Center Houston, Texas, United States